UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Pericleous C, Clarke LA, Brogan PA, Latchman DS, Isenberg DA, Ioannou Y, Giles IP, Rahman A
  • Publication date:
    01/2013
  • Pagination:
    72, 78
  • Journal:
    Thromb Haemost
  • Volume:
    109
  • Issue:
    1
  • Status:
    Published
  • Country:
    Germany
  • PII:
    12-05-0346
  • Language:
    eng
  • Keywords:
    Adult, Antibodies, Antiphospholipid, Antiphospholipid Syndrome, Biomarkers, Case-Control Studies, Cell-Derived Microparticles, Cells, Cultured, E-Selectin, Female, Human Umbilical Vein Endothelial Cells, Humans, Immunoglobulin G, Middle Aged, Time Factors
Abstract
IgG antiphospholipid antibodies (aPL) exert direct effects on various cell types, contributing to the pathogenesis of thrombosis and pregnancy morbidity in patients with the antiphospholipid syndrome (APS). Some IgG samples from these patients activate endothelial cells (EC) in vitro as judged by surface expression of adhesion molecules such as E-selectin, which can promote thrombosis. Endothelial microparticles (EMP), which themselves are potentially prothrombotic, are released by activated EC. Though elevated circulating EMP levels have been reported in patients with APS, it is not known whether these EMP are released due to a direct effect of aPL on the cells. We tested the effect of purified polyclonal IgG from patients with APS (APS-IgG) and healthy controls (HC-IgG) upon cultured human umbilical vein EC (HUVEC). HUVEC exposed to APS-IgG produced significantly more EMP than those exposed to HC-IgG (p=0.0036) and a greater proportion of these EMP carried surface E-selectin (6.2% ± 4.0 for APS-IgG vs. 3.4% ± 2.0 for HC IgG, p=0.0172). This study therefore demonstrates that purified polyclonal APS-IgG can drive EMP release. We propose that EMP generation may be a useful measure of aPL-mediated pathogenic effects upon EC.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers Show More
Author
Infection, Immunity & Inflammation Dept
Author
Inflammation
Author
Div of Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by